HLBC Investor Conference Call
The Company will be conducting an investor conference call tomorrow at 11:00am EDT to discuss this investment, and Heartland Bridge Capital's overall business strategy.
Date: Friday, October 14, 2011
Time: 11:00 a.m. (EDT)
Dial-in Number: (712) 432-0900
It is recommended that participants phone-in 5 to 10 minutes prior to the start of the call.
Following the event, a replay of the conference call will be available by calling (712) 432-0990, and entering pass code 316914.
About HepatoChem, Inc
HepatoChem is a chemistry based technology platform company with a primary focus on metabolite production from bioactive small molecules. Founded by Marc Bazin, previously with Pfizer, Inc., and Prof. John T. Groves, the Hugh Stott Taylor Chair of Chemistry at Princeton University, HepatoChem is dedicated to developing technologies that help pharmaceutical companies improve the quality of drug development pipelines. HepatoChem offers a unique and powerful solution to resolve the lack of rapid and efficient metabolite access in drug discovery. www.hepatochem.com
About Heartland Bridge Capital, Inc.
Heartland Bridge Capital, Inc. (OTCBB:HLBC) is a public company that, in addition to managing its own operating entities, participates in emerging companies run by exceptionally talented entrepreneurs and operating executives who are dedicated to creating positive change in our world. HLBC will function as an owner, product developer, and investor focused primarily on providing equity, acquisition debt, or bridge financing to emerging high-growth companies and entrepreneurs in the areas of clean energy, waste management, life sciences, and digital document services.
|SOURCE Heartland Bridge Capital, Inc.|
Copyright©2010 PR Newswire.
All rights reserved